| Literature DB >> 26288844 |
Nathan I Nicely1, Kevin Wiehe1, Thomas B Kepler2, Frederick H Jaeger1, S Moses Dennison1, Supachai Rerks-Ngarm3, Sorachai Nitayaphan4, Punnee Pitisuttithum5, Jaranit Kaewkungwal5, Merlin L Robb6, Robert J O'Connell4, Nelson L Michael7, Jerome H Kim7, Hua-Xin Liao1, S Munir Alam1, Kwan-Ki Hwang1, Mattia Bonsignori1, Barton F Haynes1.
Abstract
Human monoclonal antibody CH58 isolated from an RV144 vaccinee binds at Lys169 of the HIV-1 Env gp120 V2 region, a site of vaccine-induced immune pressure. CH58 neutralizes HIV-1 CRF_01 AE strain 92TH023 and mediates ADCC against CD4 + T cell targets infected with CRF_01 AE tier 2 virus. CH58 and other antibodies that bind to a gp120 V2 epitope have a second light chain complementarity determining region (LCDR2) bearing a glutamic acid, aspartic acid (ED) motif involved in forming salt bridges with polar, basic side amino acid side chains in V2. In an effort to learn how V2 responses develop, we determined the crystal structures of the CH58-UA antibody unliganded and bound to V2 peptide. The structures showed an LCDR2 structurally pre-conformed from germline to interact with V2 residue Lys169. LCDR3 was subject to conformational selection through the affinity maturation process. Kinetic analyses demonstrate that only a few contacts were responsible for a 2000-fold increase in KD through maturation, and this effect was predominantly due to an improvement in off-rate. This study shows that preconformation and preconfiguration can work in concert to produce antibodies with desired immunogenic properties.Entities:
Keywords: Antibody maturation; Germline; Gp120; HIV-1; RV-144; Unmutated ancestor; V2
Mesh:
Substances:
Year: 2015 PMID: 26288844 PMCID: PMC4534707 DOI: 10.1016/j.ebiom.2015.06.016
Source DB: PubMed Journal: EBioMedicine ISSN: 2352-3964 Impact factor: 8.143
Fig. 1Epitope mapping of CH58-UA and CH58 mAbs. A) The epitope for the CH58-UA monoclonal antibody was mapped in SPR using sequentially Ala-substituted AE.CM244V2-171 peptides (gp120166–186). The response from each experiment was normalized to that of wild-type peptide for comparative purposes. The graph is truncated at a two-fold response ratio to emphasize losses of binding. The substitutions that gave responses above two-fold are specified over their columns. The asterisk next to Ala174 indicates that it was substituted with Glu to distinguish that peptide from wild-type and to impart a contrasting charge character to the predominantly positively charged V2 peptide N-terminal region. B) The epitope for the mature CH58 mAb was previously mapped in ELISA (Liao et al., 2013) and is included here for comparative purposes. C) Example SPR sensograms are shown for some of the Ala-substituted peptides in the CH58-UA study. Wild-type peptide binding levels were taken into account to normalize data for presentation in this single plot.
Fig. 2Binding of CH58-UA and CH58 to wild-type and Ala-substituted gp120165–182 peptides. A) Results from BLI showing binding between CH58-UA Fab fragment and gp120165–182 V2 peptide variants. B) The shift in wavelength during the last 20 s of the dissociation phase of CH58-UA binding to the peptides shown in panel A was averaged and normalized to that of wild type peptide for comparative purposes. The error bars denote the standard deviation in the values determined from triplicate measurements. C) Representative BLI sensograms are shown for detailed kinetic experiments with wild-type gp120165–182 V2 peptide and CH58-UA Fab. Likewise, D) mature CH58 Fab with wild-type peptide and E) CH58-UA Fab with gp120165–182 Leu179Ala,Ile181Ala. In these experiments, the gp41 MPER-specific 13H11 Fab was used as negative control to subtract non-specific binding to the peptide as standard good practice. The ka, kd and derived KD values were obtained by global fitting of specific binding sensograms to a 1:1 binding model. Example measurements are reported in these panels. Average KD values are reported in the text for duplicate (CH58-UA Fab) and triplicate (CH58 Fab) measurements.
Fig. 3CD data for gp120165–182 peptide and two of its Ala-substituted variants. CD spectra for the gp120165–182 peptide and its Ala-substituted variants Leu179Ala and Leu179Ala, Ile181Ala.
Data collection and refinement statistics for the structures.
| Structure | CH58-UA | CH58-UA–gp120165–182 Leu179Ala,Ile181Ala |
|---|---|---|
| Space group: | P21 | P21 |
| Cell dimensions | ||
| a, b, c (Å): | 53.7, 103.7, 101.2 | 55.7, 53.9, 73.6 |
| α, β, γ (°): | 90.0, 100.5, 90.0 | 90.0, 108.9, 90.0 |
| Resolution (Å): | 50–2.5 (2.54–2.50) | 50–2.3 (2.34–.30) |
| Rmerge (%): | 13.1 (42.6) | 11.4 (36.6) |
| < I/σ > | 7.9 (2.0) | 19.0 (3.4) |
| Completeness (%): | 97.4 (93.9) | 99.9 (99.5) |
| Redundancy: | 3.3 (3.0) | 6.1 (5.2) |
| Total # reflections: | 36,924 | 18,762 |
| Unique # reflections: | 33,979 | 18,258 |
| Rwork/Rfree (%): | 22.0/28.9 (30.8/43.0) | 16.1/24.6 (19.3/31.4) |
| Average B factor (Å2): | 26.35 | 30.25 |
| Nonhydrogen atoms | 6578 | 3461 |
| Water molecules: | 112 | 239 |
| R.M.Scuu deviations | ||
| Bond lengths (Å): | 0.005 | 0.007 |
| Bond angles (°): | 0.943 | 1.136 |
| ψ, φ favored (%): | 96.6 | 96.2 |
| ψ, φ allowed (%): | 3.0 | 3.4 |
| zψ, φ outlying (%): | 0.4 | 0.5 |
This crystal had two Fabs in the asymmetric unit.
Values in parentheses are for the highest resolution shells.
Not including water molecules.
Fig. 4LCDR2 and ED motif interactions. A) The unliganded structures of CH58-UA and mature CH58 (with superimposed V2 peptide) showed that the Lys169 salt bridge with Glu50 in LCDR2 was pre-configured. In contrast, the disordered HCDR3 (indicated by spheres) offered no stable contacts. B) The liganded CH58-UA and mature CH58 structures showed that the hydrogen bond between Gly100E(H) and Lys169(V2) required ordering of HCDR3, whereas the ability to form the salt bridge between Glu50(L) in LCDR2 and Lys169(V2) was pre-conformed in CH58-UA.
Fig. 5Specific polar interactions between antibody and epitope gained through maturation. A) Asp31(L) in mature CH58 forms a salt bridge with Lys171(V2) and is additionally stabilized by a salt bridge with Arg25(L). In CH58-UA the salt bridge with Arg25(L) is present as are the proximity and geometry necessary to interact with V2, except that Asn31(L) clearly lacks the functional group necessary. B) Arg28(H) in mature CH58 forms a salt bridge with Asp180(V2), helping to anchor the C-terminus of the V2 peptide. However in CH58-UA, Ser28(H) is unable to make any such interaction with V2 peptide. In fact the C-terminus of the peptide in the CH58-UA complex structure is disordered without this interaction, and Asp180(V2) is not present in the structure as a result.
Fig. 6LCDR3 conformational ordering through maturation. A) In CH58-UA, LCDR3 exhibited different conformations between its unliganded and liganded states. In a superposition between the unliganded (green) and liganded (cyan and orange as labeled) structures, Tyr91(L) in the unliganded conformation clashed with overlaid Leu175(V2) from the complex structure. HCDR3 is additionally indicated for reference. B) In the mature CH58, LCDR3 exhibited the same conformation in both unliganded and liganded states, and this conformation differed from either of those observed in the CH58-UA structures. HCDR3 is also labeled here, though it was disordered in the unliganded mature CH58 structure (Liao et al., 2013).